About Immunis
Immunis is a Healthcare company based in Irvine (United States) founded in 2018. It operates as a cell therapies for age- and disease-related immune deficits are developed. Immunis has raised $67.36 million across 4 funding rounds from investors including Remiges Ventures, Continuum Health Ventures and Bold Capital Partners. Immunis offers products and services including IMM01-STEM. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Diversified. Its legal entity is Immunis, Inc. Its competitors include Flexion Therapeutics, Formation Bio, NuVasive, Ensoma and Eupraxia Pharmaceuticals and 3 more; 8 of its 8 listed competitors have raised funding.
Company details
Developer of cell therapies for age-related and disease-related immune deficits. It offers a STEM product line developed from human stem cells that secrete immune modulators for treating muscle atrophy in patients with knee osteoarthritis and muscle performance in seniors with obesity and muscle weakness.
- Headquarters Irvine, United States
- SectorsHealthcare
- Email••••••••
- Website immunisbiomedical.com/home
- Social LinkedIn Instagram YouTube
- Legal Name Immunis, Inc.
- Total Equity Funding$67.36M (USD)
in 4 rounds
- Latest Funding Round$11.98M (USD), Series A
May 2026
- InvestorsRemiges Ventures
& 4 more
Products & Services of Immunis
Immunis offers a comprehensive portfolio of products and services, including IMM01-STEM.
Improves muscle mass and immune function in age-related diseases.
Apps and channels of Immunis
its YouTube channel Immunis Inc. has 3.25K subscribers and 23 videos.
Videos from Immunis
The most watched videos on Immunis's YouTube channel, Immunis Inc. (3.25K subscribers). Click a video to play it here.
More on Immunis Inc..
Funding Insights of Immunis
Immunis has successfully raised a total of $67.36M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $11.98 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $67.36M
- Total Rounds 4
- Last Round Series A — $11.98M
- First Round $10M
(Aug 2022)
- Investors Count 5
All 4 funding rounds of Immunis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2026 | $11.98M | Series A | – | – | – |
| Jan 2025 | $25M | Series A | – | – | |
| Jun 2024 | $20.39M | Series A | – | – | – |
| Aug 2022 | $10M | Series A | – | Remiges Ventures | – |
5 investors in total: 5 institutional.
Investors in Immunis
Immunis has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Remiges Ventures, Continuum Health Ventures and Bold Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Remiges Ventures is engaged in biotech venture capital investments. | – | remigesventures.com | Seattle, United States | |
- | – | continuumhealth.vc | - | |
Early-stage life sciences and tech focused VC firm investing primarily in the US | – | boldcapitalpartners.com | Santa Monica, United States | |
- | – | lifespanvisionventures.com | - | |
- | – | jls.fund | - |
Investor details for Immunis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Immunis
9 people are tracked at Immunis (1 in leadership, 7 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Neil Sahota | Chief Artificial Intelligence Officer | Leadership |
Robert Cockrell | Chairman, Scientific Advisory Board | Board & advisors |
Micah Drummond | Scientific Advisory Board Member | Board & advisors |
Peter Diamandis | Executive Advisory Board Member | Board & advisors |
Taka Koda | Board Member | Board & advisors |
Daniel Kraft | Board Member | Board & advisors |
Chris Schaumburg | Scientific Advisory Board Member | Board & advisors |
Craig Walsh | Scientific Advisory Board Member | Board & advisors |
Hans S. Keirstead | Chairman | Team |
Complete people profiles for Immunis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Immunis
3 dated milestones of Immunis across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Immunis is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Series A, of $12.0M.
Competitors of Immunis
Immunis has 8 listed competitors in our database, 8 of them funded. They include Flexion Therapeutics, Formation Bio, NuVasive, Ensoma and Eupraxia Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| formation.bio | 2016 | New York, United States | $608.25M | – | AI-powered drug discovery platform for various diseases | |
| nuvasive.com | 1997 | San Diego, United States | $54.1M | 2,450 | Smart surgical devices for spinal surgery are developed. | |
| ensoma.com | 2019 | Boston, United States | $205M | 52 | Provider of in vivo stem cell modification technologies and vector-based drug delivery tool | |
| eupraxiapharma.com | 2012 | Vancouver, Canada | $2.44M | – | Sustained-release drug delivery platform for osteoarthritis therapies is developed. | |
| mrmhealth.com | 2020 | Ghent, Belgium | $79.18M | 29 | Developer of optimized consortia therapeutics targeting inflammatory, CNS, and metabolic diseases | |
| arthexbiotech.com | 2018 | Valencia, Spain | $93.61M | – | Oligonucleotide therapies for neuromuscular diseases like Myotonic Dystrophy are developed. | |
| tissuegene.com | 1999 | Rockville, United States | $94.64M | 29 | Regenerative cell therapies for orthopedic diseases are developed. |
Detailed competitors of Immunis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Immunis
The website of Immunis (immunisbiomedical.com) receives about 2.2K visits a month.
- Monthly visits2.2K
▼ 23.8% vs previous month
Top companies in Cell Therapy
10 companies that operate in the same segment as Immunis (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Immunis
Complete news archive for Immunis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immunis
Immunis was founded in 2018 and raised its 1st funding round 4 years after it was founded.
Immunis is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Immunis is a funded company, having raised a total of $67.36M across 4 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Aug 2022.
Developer of cell therapies for age-related and disease-related immune deficits. It offers a STEM product line developed from human stem cells that secrete immune modulators for treating muscle atrophy in patients with knee osteoarthritis and muscle performance in seniors with obesity and muscle weakness.
Immunis's top competitors include Flexion Therapeutics, NuVasive and Formation Bio.
Immunis offers IMM01-STEM.
Immunis has 5 investors. Key investors include Remiges Ventures, Continuum Health Ventures, Bold Capital Partners, LifeSpan Vision Ventures, and JLS Fund.
Immunis operates through Immunis, Inc..